US Senator Kay Hagan (D-North Carolina) has proposed legislation that aims to provide faster access to new drugs that address unmet medical needs, significantly advance the standard of care, or target a serious or life-threatening disease or condition.
The bill could also expand FDA’s use of conflict of interest waivers in forming advisory committees, a provision that may prove controversial. The legislation specifies several other process changes and enhancements (but no new funding) for the agency. More information is available on Senator Hagan’s website.
